Logo Logo
Help
Contact
Switch Language to German

Shelan, Mohamed; Aebersold, Daniel M.; Albrecht, Clemens; Boehmer, Dirk; Flentje, Michael; Ganswindt, Ute; Hoecht, Stefan; Hoelscher, Tobias; Mueller, Arndt-Christian; Niehoff, Peter; Pinkawa, Michael; Schmidt-Hegemann, Nina-Sophie; Sedlmayer, Felix; Wolf, Frank; Zamboglou, Constantinos; Zips, Daniel; Wiegel, Thomas and Ghadjar, Pirus (2021): Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO). In: Strahlentherapie und Onkologie, Vol. 197, No. 11: pp. 993-1000

Full text not available from 'Open Access LMU'.

Abstract

Purpose Various randomized phase III clinical trials have compared moderately hypofractionated to normofractionated radiotherapy (RT). These modalities showed similar effectiveness without major differences in toxicity. This project was conducted by the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society. We aimed to investigate expert opinions on the use of moderately hypofractionated RT as a definitive treatment for localized prostate cancer in German-speaking countries. Methods A 25-item, web-based questionnaire on moderate-hypofractionation RT was prepared by an internal committee. The experts of the DEGRO were asked to complete the questionnaire. Results Fourteen active members of DEGRO completed the questionnaire. The questions described indications for selecting patients eligible to receive moderate hypofractionation based on clinical and pathological factors such as age, urinary symptoms, and risk-group. The questions also collected information on the technical aspects of selection criteria, including the definition of a clinical target volume, the use of imaging, protocols for bladder and rectal filling, the choice of a fractionation schedule, and the use of image guidance. Moreover, the questionnaire collected information on post-treatment surveillance after applying moderately hypofractionated RT. Conclusion Although opinions varied on the use of moderate-hypofractionation RT, the current survey reflected broad agreement on the notion that moderately hypofractionated RT could be considered a standard treatment for localized prostate cancer in German-speaking countries.

Actions (login required)

View Item View Item